Table 2.
Univariate analysis of OS and DFS.
| Variables | OS | DFS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | 1.06 (1.02-1.12) | 0.025 | 1.12 (1.08-1.26) | 0.013 |
| BMI (kg/m2) | 1.00 (0.95-1.05) | 0.265 | 1.02 (1.00-1.16) | 0.352 |
| ASA score (III-IV) | 1.48 (1.22-1.73) | 0.016 | 1.23 (1.14-1.28) | 0.036 |
| CCI (>2) | 1.26 (1.20-1.56) | 0.035 | 1.32 (1.11-1.42) | 0.019 |
| Histologic diagnosis (Non-serous histology) | 1.35 (1.16-1.65) | <0.001 | 1.42 (1.32-1.63) | <0.001 |
| Tumor differentiation (poor) | 1.46 (1.12-1.68) | 0.035 | 1.46 (1.26-1.83) | 0.042 |
| FIGO stage (III-IV) | 1.68 (1.15-2.15) | <0.001 | 1.59 (1.12-1.78) | <0.001 |
| Residual disease (>1cm) | 1.82 (1.45-2.16) | 0.028 | 1.95 (1.26-2.06) | 0.014 |
| Surgical complexity | 1.15 (1.08-1.26) | 0.015 | 1.26 (1.22-1.56) | 0.036 |
| Ascites (ml) | 1.56 (1.42-1.98) | 0.005 | 1.15 (1.10-1.48) | 0.002 |
| Estimated blood loss (ml) | 1.22 (1.15-1.42) | 0.042 | 1.20 (1.16-1.62) | 0.034 |
| Postop-Chemotherapy (no) | 1.95 (1.24-2.16) | <0.001 | 2.16 (1.62-2.42) | <0.001 |
| Lidocaine infusion (yes) | 0.85 (0.78-0.94) | 0.026 | 0.76 (0.62-0.88) | 0.032 |
BMI, Body Mass Index; ASA, American Society of Anesthesiologists score; CCI, Charlson Comorbidity Index; FIGO, Federation International of Gynecology and Obstetrics OS, Overall Survival; DFS, Disease free Survival.